Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 24,850 Shares of Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 24,850 shares of the business’s stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total value of $1,040,966.50. Following the completion of the sale, the chief executive officer now owns 260,354 shares of the company’s stock, valued at $10,906,229.06. This trade represents a 8.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Dominick Colangelo also recently made the following trade(s):

• On Thursday, March 13th, Dominick Colangelo sold 26,592 shares of Vericel stock. The shares were sold at an average price of $45.78, for a total transaction of $1,217,381.76.

Vericel Price Performance

Shares of NASDAQ VCEL opened at $41.25 on Friday. The company has a 50 day simple moving average of $49.21 and a 200 day simple moving average of $51.42. Vericel Co. has a 1 year low of $37.76 and a 1 year high of $63.00. The firm has a market cap of $2.07 billion, a PE ratio of 687.61 and a beta of 1.61.

Analyst Upgrades and Downgrades

Several analysts have weighed in on VCEL shares. Canaccord Genuity Group lifted their price objective on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Truist Financial lowered their price objective on Vericel from $61.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. Finally, Stephens restated an “overweight” rating and issued a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Vericel currently has an average rating of “Moderate Buy” and an average price target of $60.86.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VCEL. Arcadia Investment Management Corp MI acquired a new stake in Vericel during the 4th quarter worth about $48,000. GF Fund Management CO. LTD. acquired a new position in shares of Vericel in the 4th quarter valued at about $57,000. Smartleaf Asset Management LLC boosted its position in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 1,058 shares in the last quarter. Meeder Asset Management Inc. grew its stake in Vericel by 8.4% during the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 183 shares during the period. Finally, Geneos Wealth Management Inc. increased its holdings in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,240 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.